BLAC (Bellevue Life Sciences Acquisition) Total Equity : $14.92 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Total Equity?

Bellevue Life Sciences Acquisition's total equity for the quarter that ended in Sep. 2024 was $14.92 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bellevue Life Sciences Acquisition Total Equity Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Total Equity Chart

Bellevue Life Sciences Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Equity

-0.04

32.52

Bellevue Life Sciences Acquisition Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Equity	Get a 7-Day Free Trial									68.96	32.52	32.46	15.15	14.92

Bellevue Life Sciences Acquisition Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bellevue Life Sciences Acquisition's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	36.628	-	4.108
	=	32.52

Bellevue Life Sciences Acquisition's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2024 )	-	Total Liabilities(Q: Sep. 2024 )
	=	20.926	-	6.011
	=	14.92

Bellevue Life Sciences Acquisition Total Equity Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellevue Life Sciences Acquisition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004

Website

https://www.bellevuespac.com

Bellevue Life Sciences Acquisition Corp is a blank check company.

Executives

David Jin Yoo	officer: Chief Financial Officer	(135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang	director, 10 percent owner, officer: Chief Executive Officer	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc	10 percent owner	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed	other: Director Nominee	2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung	other: Director Nominee	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh	other: Director Nominee	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park	other: Director Nominee	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang	director	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts	other: Director Nominee	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004